Antineoplastic Agents in Cancer Therapy
Uploaded by
Charles Bigalbal TuazonAntineoplastic Agents in Cancer Therapy
Uploaded by
Charles Bigalbal TuazonCommon questions
Powered by AIAsparaginase is used to treat acute lymphoblastic leukemia by depleting asparagine, an amino acid necessary for the survival of certain leukemic cells. It is prepared from Escherichia coli and functions by catalyzing the hydrolysis of asparagine to aspartic acid and ammonia, depriving the cancer cells of a critical nutrient. This treatment exploits the inability of leukemia cells to synthesize asparagine independently.
Leucovorin is a rescue agent used with methotrexate therapy to mitigate its toxic effects on normal cells. Methotrexate inhibits dihydrofolate reductase, blocking DNA synthesis in both cancerous and healthy cells. Leucovorin provides a source of reduced folate, bypassing the blocked enzyme and allowing normal cells to recover from the methotrexate-induced folate deficiency, thereby preventing severe mucositis and myelosuppression. It is administered after methotrexate to aid healthy cell recovery without supporting the survival of cancer cells.
Camptothecins, such as irinotecan and topotecan, are used in treating colorectal and small cell lung cancers, respectively. Their mechanism of action involves inhibiting topoisomerase I, an enzyme crucial for DNA unwinding and replication. By stabilizing the complex formed between topoisomerase I and DNA, camptothecins induce DNA damage and cell death, especially in rapidly proliferating cancer cells. These agents also form a part of combination therapies to enhance efficacy and minimize resistance development.
Antineoplastic agents are classified into several classes, each with specific mechanisms of action: Alkylating agents work by adding alkyl groups to the DNA, leading to DNA breakage and preventing cancer cell division. Antitumor antibiotics, such as anthracyclines, intercalate DNA and inhibit topoisomerase II, damaging DNA and preventing replication. Antimetabolites, like methotrexate, inhibit DNA synthesis by mimicking or interfering with natural metabolites. Plant alkaloids disrupt microtubules essential for cell division. Hormonal agents block hormones needed for cancer cell growth.
Cisplatin is an organoplatinum compound that forms cross-links between DNA strands, disrupting DNA synthesis and cell division. Its notable adverse drug reactions include nephrotoxicity, which affects kidney function, and ototoxicity, which can lead to hearing loss. Strategies to manage these ADRs include hydration protocols and using protective agents like amifostine.
Hydroxyurea is an antineoplastic agent used in myelogenous leukemia and thrombocytosis. Its mechanism of action involves inhibiting ribonucleotide diphosphate reductase, an enzyme crucial for DNA synthesis by converting ribonucleotides to deoxyribonucleotides. This inhibition reduces the proliferation of rapidly dividing cells by disrupting their DNA replication process. Hydroxyurea also has a role in managing sickle cell disease by increasing fetal hemoglobin levels.
Selective Estrogen Receptor Modulators (SERMs), such as tamoxifen, are used in treating estrogen receptor-positive breast cancer. They function by antagonizing estrogen receptors in breast tissue, inhibiting estrogen-driven tumor growth. Despite efficacy in reducing cancer relapse and progression, SERMs are associated with risks such as endometrial cancer and thromboembolic events, necessitating careful patient monitoring and selection to optimize therapeutic benefits while minimizing adverse outcomes.
Plant alkaloids, such as vincristine and paclitaxel, commonly cause neurological effects like peripheral neuropathy and autonomic instability. Management strategies include dose adjustments, symptomatic treatments such as anticonvulsants for neuropathic pain, and monitoring for early detection of symptoms. Additional ADRs like bone marrow suppression, particularly with paclitaxel, are managed with growth factor support and infection prophylaxis. Dose-limiting toxicities are often addressed by minimizing peripheral exposure through treatment scheduling modifications.
Aromatase inhibitors, such as anastrozole, play a crucial role in managing postmenopausal hormone-sensitive breast cancer by blocking the aromatase enzyme, which converts androgens to estrogens. This reduction in estrogen levels slows the growth of estrogen receptor-positive tumors, proving effective in preventing disease recurrence and progression. They are preferred over SERMs in certain scenarios due to their favorable risk profile concerning thromboembolism and secondary cancer risks. Selection depends on individual patient hormone receptor status and menopausal stage.
The specificity of cancer chemotherapeutic drugs to certain phases of the cell cycle is crucial because it allows targeted disruption of cancer cell proliferation during sensitive periods such as DNA synthesis (S phase) or mitosis (M phase). Agents targeting the S phase include antimetabolites, while mitotic inhibitors act during the M phase. This specificity informs combination therapy strategies, optimizing treatment efficacy by synchronizing drug administration to target multiple pathways and phases, minimizing resistance and adverse effects.
